No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 15
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for FibroBiologics, Inc. Common Stock (FBLG) stock was $1.17 as of Oct 6, 2026, 12:21 PM EDT, down 0.85% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -89.1%
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States.
Biotechnology · Houston, TX
Next Earnings Date
Oct 30, 2026
24 days away
EPS Estimate
-0.63
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.66
vs Estimate
$-0.93
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1FBLG | $2.45M | $1.17 | -0.85% | -89.14% | N/A | N/A | N/A |
| 2MBRX | $2.43M | $0.46 | -4.41% | -95.81% | -78.48% | -64.00% | vs FBLG |
| 3JAGX | $2.50M | $5.77 | +21.99% | N/A | N/A | N/A | vs FBLG |
| 4ONCO | $2.37M | $0.66 | -1.90% | -99.55% | N/A | N/A | vs FBLG |
| 5BIAF | $2.56M | $6.11 | -1.29% | -84.05% | N/A | N/A | vs FBLG |
| 6CELZ | $2.34M | $0.91 | -1.54% | -71.43% | -57.96% | -72.19% | vs FBLG |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 2 analysts
Average Price Target
$12.50
+968.4% upside
Low
$6.00
Current
$1.17
High
$19.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.63 | $-0.63 | $-0.63 | 1 |
| Quarter ending Dec 2026 | $-0.63 | $-0.63 | $-0.63 | 1 |
| Quarter ending Mar 2027 | $-0.77 | $-0.77 | $-0.77 | 1 |
| Quarter ending Jun 2027 | $-0.73 | $-0.73 | $-0.73 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.00 | $-3.00 | $-3.00 | 1 |
| FY 2027 | $-3.25 | $-3.25 | $-3.25 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
